Risk Of Developing Liver Cancer After HCV Treatment

Monday, October 12, 2015

Drug Interactions between TAF-Based Regimens and HCV Treatments in Coinfected Patients

Drug Interactions between TAF-Based Regimens and HCV Treatments in Coinfected Patients 
“No dose modification is required when co-administering single-tablet regimens containing tenofovir alafenamide to patients with HIV being treated with ledipasvir/sofosbuvir for hepatitis C virus co-infection,” said Joseph Custodio, PhD, Senior Clinical Scientist at Gilead Sciences, during a presentation at IDWeek 2015. 
 IDWeek is a joint meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). 

No comments:

Post a Comment